This study is testing a new treatment for adults with metastatic uveal melanoma, a type of eye cancer that has spread to other parts of the body. The study compares two treatments: RP2 (an experimental virus therapy) with nivolumab, and nivolumab with ipilimumab, both being cancer-fighting drugs.

To join, you must be 18 or older, have this type of cancer, and meet certain health criteria. Some of these criteria include having no prior treatment with immune checkpoint inhibitors (medicines that help your immune system fight cancer), good liver and kidney function, and no recent major surgeries.

Key Points:

• The study requires regular doctor visits for check-ups and treatments.
• Participants cannot have received specific cancer treatments or have certain infections.
• Compensation details are not specified, but you will be contributing to important cancer research.